Wells Fargo analyst David Maris said a jury's ruling that a Momenta (MNTA) patent was invalid and unenforceable is a very positive outcome for Amphastar (AMPH) in its "David-vs-Goliath-type" case. While he expects Momenta and partner Novartis' (NVS) Sandoz to appeal, Maris thinks this ruling puts Amphastar in a good position for any future potential settlement talks. Maris does not think investors should "count on any windfall" for Amphastar, but he does think, if approved, this could be an over $50M opportunity and keeps an Outperform rating on the stock, which is up 2% to $18.32 in afternoon trading.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.